Advertisement
News
Subscribe to Pharmaceutical Processing News

The Lead

Patent Expirations Hit Eli Lilly Third Quarter Profit

October 23, 2014 | Comments

Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.

TOPICS:

CDC Details New Ebola Response and Prep Teams

October 23, 2014 2:11 pm | by MIKE STOBBE, AP Medical Writer | Comments

New federal Ebola response squads — likened to public health SWAT teams — are being readied to rush to any U.S. city where a new Ebola case might be identified, officials say.             

TOPICS:

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

October 23, 2014 10:31 am | Comments

The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.

TOPICS:

Pfizer Wins SUTENT® Patent Case

October 23, 2014 10:14 am | Comments

Pfizer announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.

TOPICS:
Advertisement

GlobalData Analyst: Pharmaceutical Industry Feeling Force of Tax Inversion Legislation

October 23, 2014 9:30 am | Comments

The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.

TOPICS:

HealthCare.gov's EZ Form Not for Legal Immigrants

October 23, 2014 8:26 am | by RICARDO ALONSO-ZALDIVAR, Associated Press | Comments

HealthCare.gov's new EZ application for coverage can't be used by legal immigrants or naturalized U.S. citizens, prompting concern that many Hispanics and Asians will go right back into long enrollment queues this year.      

TOPICS:

Poll: Many Doubt Hospitals Can Handle Ebola

October 23, 2014 8:19 am | by LAURAN NEERGAARD, Associated Press; EMILY SWANSON, Associated Press | Comments

Most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient, according to an Associated Press-GfK poll.   

TOPICS:

Vaxart Accelerates Development of Ebola Tablet Vaccine

October 23, 2014 8:10 am | Comments

Vaxart, a privately held company developing vaccines that are administered by tablet rather than by injection, today announced that the company is accelerating its Ebola tablet vaccine program. Following a recent meeting with the FDA, Vaxart anticipates commencing human clinical trials in the first quarter of 2015.

TOPICS:

Eli Lilly Adds $375M to Zymeworks Partnership

October 22, 2014 5:37 pm | by The Associated Press | Comments

The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.     

TOPICS:
Advertisement

US to Track Everyone Coming from Ebola Nations

October 22, 2014 2:04 pm | by CONNIE CASS, Associated Press | Comments

Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees and journalists, as well as West African travelers.

TOPICS:

Biogen Idec Shares Slides as MS Drug is Linked to Inflammation

October 22, 2014 1:40 pm | Comments

The company confirmed there was a case of progressive multifocal leukoencephalopathy, or PML, in one patient who took the drug Tecfidera. It said the patient recently died of complications of pneumonia.         

TOPICS:

Mayne Pharma Appoints New VP of Quality for U.S. Operations

October 22, 2014 11:22 am | Comments

Q. Dwight Lewis is responsible for managing all quality-related functions to ensure that Mayne Pharma’s U.S. pharmaceutical operations – which range from laboratories to manufacturing lines – continue to comply with global regulatory agency and industry standards.

TOPICS:

Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5B

October 22, 2014 10:53 am | Comments

Biogen Idec has reported third quarter 2014 results, including revenue of $2.5B, a 37% increase compared to the third quarter of 2013. Third quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.80, an increase of 61% over the third quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the third quarter was $900M, an increase of 60% over the third quarter of 2013.

TOPICS:

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

October 22, 2014 10:43 am | Comments

The recent FDA approval of Harvoni, Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus genotype 1 infection in adults, will enable the company to maintain its dominance in an increasingly competitive market, says an analyst with research and consulting firm GlobalData.

TOPICS:

Study Finds Drugs Still in Recalled Supplements

October 22, 2014 8:58 am | by LINDSEY TANNER, AP Medical Writer | Comments

Dietary supplements containing potentially dangerous prescription drug ingredients may still be for sale even years after safety recalls, a study found. In supplements bought online, researchers detected hidden steroids, similar ingredients to Viagra and Prozac and a weight loss drug linked with heart attacks.

TOPICS:

Red Cross Official: Six Months to Contain Ebola

October 22, 2014 8:54 am | Comments

A top Red Cross official said Wednesday that he is confident the Ebola epidemic that has killed thousands of people in West Africa can be contained within four to six months.             

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading